FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125697254> ?p ?o ?g. }

• W2125697254 endingPage "344" @default.
• W2125697254 startingPage "337" @default.
• W2125697254 abstract "Purpose Personalized selection of suitable peptides for patients could offer a novel approach to developing cancer vaccines that boost anticancer immunity. We present the results of a phase I trial of 14 kinds of vaccine candidates (ITK-1) in patients with recurrent or progressive glioblastoma multiforme (GBM). Patients and Methods From January 2006 to January 2008, 12 patients from eight Japanese hospitals who were positive for human leukocyte antigen–A24, including 10 patients refractory to temozolomide (TMZ), were enrolled. The dose escalation trial included three dose groups (1, 3, and 5 mg) to determine the safety and tolerability of ITK-1 peptides. Immunologic response was monitored by measuring levels of cytotoxic T-lymphocyte precursors and peptide-specific immunoglobulin G. In another ITK-1 phase I trial for advanced prostate cancer, the vaccination schedule was skipped or discontinued in all three patients receiving the highest dose (5 mg/peptide) because of injection site reactions. This trial was therefore ended without enrollment for the highest dose, and data were analyzed by intention to treat. Results No serious adverse drug reactions were encountered, and treatment was well tolerated. The vaccine induced dose-dependent immune boosting. The recommended dose of ITK-1 peptides is 3 mg/peptide. Conclusion Personalized vaccination with ITK-1 peptides could be recommended in further stages of clinical trials. The safety and increased frequency of immune boosting offers potential clinical benefits in cases of recurrent or progressive GBM, even in TMZ-refractory settings." @default.
• W2125697254 created "2016-06-24" @default.
• W2125697254 creator A5006133126 @default.
• W2125697254 creator A5033584393 @default.
• W2125697254 creator A5034428180 @default.
• W2125697254 creator A5038116586 @default.
• W2125697254 creator A5039113744 @default.
• W2125697254 creator A5044703804 @default.
• W2125697254 creator A5063521263 @default.
• W2125697254 creator A5065124028 @default.
• W2125697254 creator A5071269946 @default.
• W2125697254 creator A5076016324 @default.
• W2125697254 creator A5086562781 @default.
• W2125697254 date "2011-01-20" @default.
• W2125697254 modified "2023-10-16" @default.
• W2125697254 title "Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen–A24 With Recurrent or Progressive Glioblastoma Multiforme" @default.
• W2125697254 cites W1530028652 @default.
• W2125697254 cites W1980785423 @default.
• W2125697254 cites W1995018466 @default.
• W2125697254 cites W1996899549 @default.
• W2125697254 cites W2002662941 @default.
• W2125697254 cites W2004999182 @default.
• W2125697254 cites W2013504286 @default.
• W2125697254 cites W2025558159 @default.
• W2125697254 cites W2051852073 @default.
• W2125697254 cites W2055283172 @default.
• W2125697254 cites W2073114277 @default.
• W2125697254 cites W2078684250 @default.
• W2125697254 cites W2080457117 @default.
• W2125697254 cites W2091666445 @default.
• W2125697254 cites W2094448081 @default.
• W2125697254 cites W2096287682 @default.
• W2125697254 cites W2098149634 @default.
• W2125697254 cites W2108177250 @default.
• W2125697254 cites W2111912457 @default.
• W2125697254 cites W2121445603 @default.
• W2125697254 cites W2124129321 @default.
• W2125697254 cites W2129153120 @default.
• W2125697254 cites W2143992630 @default.
• W2125697254 cites W2156420427 @default.
• W2125697254 cites W2157075165 @default.
• W2125697254 cites W2157270051 @default.
• W2125697254 cites W2160382843 @default.
• W2125697254 cites W2165835640 @default.
• W2125697254 doi "https://doi.org/10.1200/jco.2010.29.7499" @default.
• W2125697254 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21149665" @default.
• W2125697254 hasPublicationYear "2011" @default.
• W2125697254 type Work @default.
• W2125697254 sameAs 2125697254 @default.
• W2125697254 citedByCount "105" @default.
• W2125697254 countsByYear W21256972542012 @default.
• W2125697254 countsByYear W21256972542013 @default.
• W2125697254 countsByYear W21256972542014 @default.
• W2125697254 countsByYear W21256972542015 @default.
• W2125697254 countsByYear W21256972542016 @default.
• W2125697254 countsByYear W21256972542017 @default.
• W2125697254 countsByYear W21256972542018 @default.
• W2125697254 countsByYear W21256972542019 @default.
• W2125697254 countsByYear W21256972542020 @default.
• W2125697254 countsByYear W21256972542021 @default.
• W2125697254 countsByYear W21256972542022 @default.
• W2125697254 countsByYear W21256972542023 @default.
• W2125697254 crossrefType "journal-article" @default.
• W2125697254 hasAuthorship W2125697254A5006133126 @default.
• W2125697254 hasAuthorship W2125697254A5033584393 @default.
• W2125697254 hasAuthorship W2125697254A5034428180 @default.
• W2125697254 hasAuthorship W2125697254A5038116586 @default.
• W2125697254 hasAuthorship W2125697254A5039113744 @default.
• W2125697254 hasAuthorship W2125697254A5044703804 @default.
• W2125697254 hasAuthorship W2125697254A5063521263 @default.
• W2125697254 hasAuthorship W2125697254A5065124028 @default.
• W2125697254 hasAuthorship W2125697254A5071269946 @default.
• W2125697254 hasAuthorship W2125697254A5076016324 @default.
• W2125697254 hasAuthorship W2125697254A5086562781 @default.
• W2125697254 hasBestOaLocation W21256972541 @default.
• W2125697254 hasConcept C126322002 @default.
• W2125697254 hasConcept C143998085 @default.
• W2125697254 hasConcept C147483822 @default.
• W2125697254 hasConcept C195616568 @default.
• W2125697254 hasConcept C197934379 @default.
• W2125697254 hasConcept C203014093 @default.
• W2125697254 hasConcept C22070199 @default.
• W2125697254 hasConcept C2776694085 @default.
• W2125697254 hasConcept C2776789287 @default.
• W2125697254 hasConcept C2777389519 @default.
• W2125697254 hasConcept C2778375690 @default.
• W2125697254 hasConcept C535046627 @default.
• W2125697254 hasConcept C71924100 @default.
• W2125697254 hasConcept C8891405 @default.
• W2125697254 hasConceptScore W2125697254C126322002 @default.
• W2125697254 hasConceptScore W2125697254C143998085 @default.
• W2125697254 hasConceptScore W2125697254C147483822 @default.
• W2125697254 hasConceptScore W2125697254C195616568 @default.
• W2125697254 hasConceptScore W2125697254C197934379 @default.
• W2125697254 hasConceptScore W2125697254C203014093 @default.
• W2125697254 hasConceptScore W2125697254C22070199 @default.
• W2125697254 hasConceptScore W2125697254C2776694085 @default.
• W2125697254 hasConceptScore W2125697254C2776789287 @default.

• next